# A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma

> **NCT06381583** · — · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 658 (actual)

## Conditions studied

- Esophagus Cancer
- Esophageal Cancer Stage
- Esophageal Cancer
- Esophageal Neoplasms
- Esophagus Adenocarcinoma
- Esophagus, Barrett
- Barrett Esophagus
- Barrett Adenocarcinoma
- Barrett Epithelium
- Barretts Esophagus With Dysplasia
- Barrett's Esophagus Without Dysplasia
- Barretts Esophagus With High Grade Dysplasia
- Barretts Esophagus With Low Grade Dysplasia
- Barrett Esophagus, Long-Segment
- Barrett's Esophagus With Dysplasia, Unspecified
- Barrett's Esophagus With Esophagitis
- Gastroesophageal Reflux
- Reflux Disease
- Esophageal Adenocarcinoma
- Esophageal Dysplasia
- Esophageal Neoplasms Malignant

## Interventions

- **DIAGNOSTIC_TEST:** EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)

## Key facts

- **NCT ID:** NCT06381583
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-15
- **Primary completion:** 2024-04-24
- **Final completion:** 2024-04-24
- **Target enrollment:** 658 (ACTUAL)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06381583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06381583, "A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06381583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*